Chemotherapy Regimens: — What the Acronyms Mean

FOLFOX stands for Folinic acid (leucovorin), 5-Fluorouracil (5-FU), and Oxaliplatin. Folinic acid is not itself a chemotherapy drug — it is given to enhance the effect of 5-fluorouracil. Oxaliplatin is a platinum-based agent given intravenously. FOLFOX is most commonly used in colorectal cancer. The number of planned cycles varies by stage and response; ask your oncologist how many are planned for your situation rather than looking for a standard figure.

FOLFIRI stands for Folinic acid (leucovorin), 5-Fluorouracil, and Irinotecan. It uses the same folinic acid and 5-fluorouracil backbone as FOLFOX but replaces oxaliplatin with irinotecan, a different class of drug. FOLFIRI and FOLFOX may be used at different points in treatment, or one may follow the other. The choice depends on your specific situation, prior treatment history, and how your body tolerated earlier drugs.

FOLFIRINOX combines all four drugs: Folinic acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin. The name is assembled from FOL (folinic acid), F (5-fluorouracil), IRIN (irinotecan) and OX (oxaliplatin). It is an intensive combination typically considered for patients with good general fitness. It is associated with a higher rate of side effects than simpler regimens, which is why a detailed fitness assessment takes place before it is recommended.

CHOP stands for Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisolone. When rituximab — a monoclonal antibody that targets the CD20 protein on certain lymphoma cells — is added, the regimen becomes R-CHOP. R-CHOP is among the most widely used regimens in lymphoma treatment. Cycle counts are set in advance and reviewed after an interim assessment scan, typically partway through the planned course.

ABVD stands for Doxorubicin (Adriamycin), Bleomycin, Vinblastine, and Dacarbazine. It has been a standard regimen for Hodgkin lymphoma for several decades, which is why it uses the Adriamycin brand name rather than the generic. All four drugs are given intravenously. Bleomycin carries a specific lung toxicity risk, so your team will monitor your breathing throughout treatment and may order lung function tests at intervals.

AC-T is a sequential regimen, not a single combination given at the same time. AC stands for Doxorubicin (Adriamycin) and Cyclophosphamide, given together in the first phase. T stands for Taxol — the brand name for paclitaxel — given in a separate second phase after AC is complete. The hyphen in the name signals the sequence. A related version uses docetaxel instead of paclitaxel and may appear as AC-D or AC-Doc on your paperwork.

BEP stands for Bleomycin, Etoposide, and Cisplatin (formerly marketed as Platinol, which provides the P). It is used most commonly in germ cell tumours, including testicular cancer. Cisplatin is given intravenously and requires careful hydration before and after each administration to protect the kidneys — your nurses will manage this as part of each treatment day. Bleomycin carries a lung toxicity risk your team will monitor throughout.

CAPOX and XELOX are two names for the same regimen: Capecitabine and Oxaliplatin. Capecitabine — sold under the brand name Xeloda, which gives XELOX its name — is an oral tablet taken at home on a schedule your team will write out for you. Oxaliplatin is given intravenously in the clinic. Because part of your treatment happens outside the hospital, your team will give you written instructions on timing, storage and what to watch for between visits.

GC stands for Gemcitabine and Cisplatin. It is used across several cancer types, including non-small-cell lung cancer, bladder cancer, and cancers of the bile duct and gallbladder. Both drugs are given intravenously. Cisplatin requires hydration before and after administration. Some patients receive carboplatin instead of cisplatin — the same class of platinum drug — if kidney function or other factors make cisplatin unsuitable. Your oncologist will specify which platinum agent is in your plan.

FEC stands for 5-Fluorouracil, Epirubicin, and Cyclophosphamide. Epirubicin is a red-coloured drug that may turn urine pink or red for a day or two after treatment — this is expected and not a cause for alarm. FEC is sometimes followed by a taxane drug in a sequential plan, written FEC-T or FEC-D depending on which taxane follows. The number of FEC cycles before any switch is set out in your individual treatment plan.

ECF stands for Epirubicin, Cisplatin, and 5-Fluorouracil. ECX replaces the continuous-infusion 5-fluorouracil component with oral capecitabine (Xeloda), which achieves a similar effect without requiring a portable infusion pump to be worn at home. Both are used in cancers of the stomach and oesophagus. The choice between ECF and ECX depends on your oncologist's assessment of which delivery method suits your situation and how you are likely to tolerate each.

CMF stands for Cyclophosphamide, Methotrexate, and 5-Fluorouracil. It is an older regimen that predates the anthracycline-based combinations more commonly used today. It may still be chosen in specific situations — for example, where cardiac considerations make doxorubicin or epirubicin unsuitable. If you see CMF on your paperwork and were not expecting it, ask your oncologist to explain the reasoning, as it will be specific to your individual circumstances.